Intra- and extra- articular LP-PRP Injection for Osteoarthritis

Phase 1

Waitlist Available

Led By Sean W Mulvaney, MD

Research Sponsored by Regenerative Orthopedics and Sports Medicine

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12 months

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing whether one injection of leukocyte-poor platelet-rich plasma (LP-PRP) into the intra-articular (IA) space of the hip improves symptoms of hip OA over 12 months, and whether adding an injection into the surrounding extra-articular (EA) structures improves symptoms more.

Eligible Conditions

Osteoarthritis
Degeneration

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Hip Osteoarthritis Outcome Score for Joint Replacement (HOOS JR)

Numeric Rating Scale

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Intra- and extra- articular LP-PRP InjectionExperimental Treatment1 Intervention

A single injection of LP-PRP will be administered to the intra- articular space and the extra- articular structures under ultrasound guidance at the first visit.

Group II: Intra-articular LP-PRP InjectionActive Control1 Intervention

A single injection of leukocyte poor platelet rich plasma (LP-PRP) will be administered to the intra-articular space under ultrasound guidance at the treatment visit.

Do I qualify?Apply below to find out